Dolby Laboratories, Inc.
DLB · NYSE
3/28/2025 | 12/27/2024 | 9/30/2024 | 6/28/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.62 | -0.65 | 0.15 | -0.81 |
| FCF Yield | 2.18% | 1.33% | 1.49% | 0.18% |
| EV / EBITDA | 48.30 | 62.35 | 80.48 | 96.05 |
| Quality | ||||
| ROIC | 3.09% | 2.47% | 1.63% | 1.23% |
| Gross Margin | 90.30% | 88.58% | 88.85% | 87.65% |
| Cash Conversion Ratio | 2.47 | 1.45 | 1.90 | 1.57 |
| Growth | ||||
| Revenue 3-Year CAGR | 1.25% | 1.52% | 1.07% | 2.06% |
| Free Cash Flow Growth | 68.00% | -8.08% | 696.95% | -92.09% |
| Safety | ||||
| Net Debt / EBITDA | -4.91 | -5.10 | -6.31 | -10.18 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 1.04 | 1.28 | 1.01 | 1.03 |
| Cash Conversion Cycle | 176.06 | 186.00 | 194.74 | 194.72 |